Vish_ram Posted May 30, 2014 Share Posted May 30, 2014 This is a company Gio might love. Martin Shkreli is the CEO and founder. It has had a controversial beginnings with going public from a reverse merger. The CEO is young, brash with a terrific record in a biotech hedge fund. He has earned the wrath of many biotech investors by going short. His record is here http://seekingalpha.com/author/martin-shkreli/instablog He calls RTRX a M&A company. He has bought companies in quick succession. The PR http://finance.yahoo.com/news/retrophin-enters-u-license-agreement-204100983.html . If the forecasts become true, it will trade at a P/E multiple of 10 or less. Shkreli is young (31), brilliant, hungry and raring to go. this article sums up everything about him. He has the unique experience of being in hedge fund, and now in operations. He doesn't court sell side analysts. http://www.businessweek.com/articles/2014-04-17/retrophins-martin-shkreli-the-biotech-short-seller-who-went-long?campaign_id=yhoo This is a biotech and risky. But this is a co to watch. I like his strategy of acquisition, raising prices (Like Qcor's Acthar), and laser focus on rare disease areas. His twitter posts are sometimes unprofessional (like F U). You'll hear more about him & Retrophin in the future. Disclaimer: I've a small position Link to comment Share on other sites More sharing options...
Andy Dufresne Posted May 30, 2014 Share Posted May 30, 2014 Thanks for this Vish_ram! Shkreli seems like a colorful guy who'd be interesting to follow ... Link to comment Share on other sites More sharing options...
ItsAValueTrap Posted May 30, 2014 Share Posted May 30, 2014 They used to borrow money at extremely high interest rates in the past. Usually not a good sign. G&A is also rather high. Then again, Martin Shkreli seems like a maverick and he is very smart. Even smart enough to paint the tape with insider buying. I don't think I'd want to go long biotechs right now given the valuations. Biotech is probably in a bubble right now. *Disclosure: Shorted this in the past, covered at a very small profit. There are many better biotech shorts out there. Link to comment Share on other sites More sharing options...
Liberty Posted March 9, 2018 Share Posted March 9, 2018 https://www.cnbc.com/2018/03/09/pharma-bro-martin-shkreli-sentenced-to-7-years-in-prison.html Link to comment Share on other sites More sharing options...
rb Posted March 10, 2018 Share Posted March 10, 2018 Here's the really depressing thing. After Liberty posted here I've read the thread. All previous posters spoke glowingly about this scumbag. Link to comment Share on other sites More sharing options...
LowIQinvestor Posted June 12, 2019 Share Posted June 12, 2019 Cuurent market Cap = $790M Commercial portfolio generates at least $165M a year & they have $440M in cash on balance sheet ( downside protection) Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals) Anyone follow RTRX? Link to comment Share on other sites More sharing options...
ander Posted June 13, 2019 Share Posted June 13, 2019 Cuurent market Cap = $790M Commercial portfolio generates at least $165M a year & they have $440M in cash on balance sheet ( downside protection) Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals) Anyone follow RTRX? Your friend have any idea why the stock has been lagging or why it's trading cheap on the numbers. I wonder if there is a concern if their existing revenue goes away so not really as cheap as it screens? Link to comment Share on other sites More sharing options...
gfp Posted June 13, 2019 Share Posted June 13, 2019 You'll hear more about him & Retrophin in the future. This was prescient! Link to comment Share on other sites More sharing options...
given2invest Posted June 13, 2019 Share Posted June 13, 2019 Cuurent market Cap = $790M Commercial portfolio generates at least $165M a year & they have $440M in cash on balance sheet ( downside protection) Friend at biotech fund says this is interesting risk/reward given a number of upcoming catalysts ( potential FDA approvals) Anyone follow RTRX? The revs are trash. They came from buying old drugs and hiking the prices a gazillion percent. That's why it screens so cheap. Google Martin Shkreli retrophin and get out the popcorn. The real catalysts are the upcoming trial readouts which I have no view on. Your friend have any idea why the stock has been lagging or why it's trading cheap on the numbers. I wonder if there is a concern if their existing revenue goes away so not really as cheap as it screens? Link to comment Share on other sites More sharing options...
LowIQinvestor Posted June 24, 2019 Share Posted June 24, 2019 Potential Catalyst at the end of this week: PDUFA date of June 30, 2019 for new, more patient-friendly formulation of Thiola; pending approval, the Company expects to begin marketing the new formulation in the second half of 2019 Link to comment Share on other sites More sharing options...
LowIQinvestor Posted June 28, 2019 Share Posted June 28, 2019 I couldn't resist I bought some RTRX calls Seems way too cheap Link to comment Share on other sites More sharing options...
LowIQinvestor Posted June 28, 2019 Share Posted June 28, 2019 RTRX!! http://www.globenewswire.com/news-release/2019/06/28/1876255/0/en/Retrophin-Announces-FDA-Approval-of-THIOLA-EC-tiopronin-100mg-and-300mg-Tablets-for-the-Treatment-of-Cystinuria.html?culture=en-us Link to comment Share on other sites More sharing options...
ander Posted June 29, 2019 Share Posted June 29, 2019 Nice. Which calls did you buy? What do you think this means for value? Link to comment Share on other sites More sharing options...
LowIQinvestor Posted July 10, 2019 Share Posted July 10, 2019 Read this-Multiple more catalysts Retrophin: Highly Investable, Except For A 'Pharma Bro' Problem https://seekingalpha.com/article/4274126-retrophin-highly-investable-except-pharma-bro-problem Link to comment Share on other sites More sharing options...
ander Posted August 7, 2019 Share Posted August 7, 2019 Results seemed fine. One trial delayed enrollment a few months. See any news why down 20%? Link to comment Share on other sites More sharing options...
ander Posted August 28, 2019 Share Posted August 28, 2019 Read this-Multiple more catalysts Retrophin: Highly Investable, Except For A 'Pharma Bro' Problem https://seekingalpha.com/article/4274126-retrophin-highly-investable-except-pharma-bro-problem Looks like 1 of the 3 Phase 3 trials failed. At these valuation levels (about $150 million of enterprise value, or $400 million including convert due in 2025), burned $50 million of cash last year, seems like you're not paying much for the company. Might be even better risk/reward here even with the 1 failed Phase 3. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now